Patient Area

Information, resources and support for patients and their loved ones.

Ressources

The Role of Patients in OASIS

Patients are at the heart of the OASIS project. Their experience, voice, and engagement are essential to advancing research. That is why OASIS is built on a philosophy of co-creation with patients, notably supported by Unicancer and Cancer Patients Europe.

This collaboration has two main goals

  • R
    Ensure that protocols are understandable, acceptable, and respectful of patients’ realities
  • R
    Promote research that is more ethical, relevant, and aligned with the real expectations of those affected by cancer

This innovative approach to clinical research includes

  • R
    Patient involvement in steering committees of clinical trials
  • R
    Systematic review of participant documents (informed consent forms, questionnaires, information brochures)
  • R
    Integration of quality-of-life questionnaires to better understand the daily impact of ADCs
  • R
    Support for patients throughout their participation to ensure clear, transparent, and accessible information

Our ambition is that every patient is fully informed, respected, and supported if they choose to participate in the study.

Identify the best ADC for each patient

All data collected within the project will feed the development of a multimodal predictive model based on artificial intelligence: the OASIS score.

This score will estimate, according to the specific characteristics of each patient and each tumor, the probability of response to a given ADC as well as the associated risk of toxicity, with the goal of optimally guiding therapeutic decisions.

The program will thus identify the most suitable technologies to predict response to an ADC, with a view to developing them as companion diagnostics.

Better predict secondary effects

ADCs are powerful targeted therapies but can cause certain side effects, sometimes severe. These adverse effects vary between patients and may include:

  • Pulmonary inflammation (interstitial lung diseases)
  • Peripheral neuropathies (numbness, tingling, pain)
  • Skin or digestive toxicities

A key objective of the OASIS project is to better anticipate and prevent these side effects by identifying toxicity biomarkers. By understanding how and why these effects occur, doctors will be able to tailor treatment choices or monitoring accordingly, thereby improving patients’ quality of life.